Outcome of Treatment of Giant-Cell Tumor of Bone: a Single-Institutional Retrospective Study

Abstract

Background: Giant-cell tumor of bone (GCTB) is a locally aggressive tumor which metastasizes infrequently to the lungs. The standard treatment of GCTB was surgery until the approval of denosumab. Aim: To describe the outcome of treatment of this rare tumor and to determine factors that influence survival. Methods: Retrospective review of the medical records of GCTB patients treated at our institution. Collected data includes: clinicopathological data, treatment modalities and possible prognostic factors. Results: Forty-two patients were identified between May 2008 and November 2017. Their median age was 31 years, and the majority (62%) were females. The commonest primary sites were the upper and lower limbs (50% and 43%, respectively). Eight (19%) patients initially presented with lung metastases. Thirteen (31%) patients received denosumab as first line treatment before surgery and 12 of them underwent surgery post-denosumab. Denosumab was given after recurrence in 12 (29%) patients [8 (19%) with lung metastasis and 4 (10%) with localized disease]. The objective response rate to denosumab after recurrence was 50%. Four (10%) patients achieved complete response and 2 (5%) partial response. After a median follow up of 4.7 years, 6 (14%) patients had local recurrence and 8 (19%) had lung metastasis with no recorded deaths. The 5-year progression-free survival rate was 61%. Conclusion: Denosumab is effective and tolerable in the management of GCTB preoperatively in localized disease to facilitate surgery and in the management of metastatic disease. Multi-institutional prospective studies are needed for further assessment.

The Effectiveness of Denosumab in Middle Eastern Patients With Giant Cell Tumor of the Bone: A Single-Center, Retrospective Study

“…All patients with histological confirmation of GCTB at our center were included in the study. We included some patients from a previous study that studied the prognosis of patients with GCTB on denosumab [ 6 ]. One of the limitations of the previous study is the smaller proportion of denosumab patients compared to non-denosumab patients.…”

“…Although recent studies have shown promising outcomes with denosumab, the long-term effects of denosumab have not been studied extensively. Additionally, studies analyzing the long-term effects of denosumab in the Middle Eastern region are limited by their small sample size [ 6 ]. Therefore, in this study, we compare the progression-free survival (PFS) of patients with GCTB who received denosumab versus those who did not.…”

Outcome and prognostic factors of low‑grade serous ovarian cancer: An observational retrospective study

“…The abstract was presented at the European Society of Gynecological Oncology Congress, March 7-10 2024 in Barcelona, Spain, and published as abstract 391 in the International Journal of Gynecological Cancer ( 39 ).…”

Outcomes in Bone Giant Cell Tumors Treated With Surgical Resection With and Without Denosumab Injection: A Single-Institution Retrospective Study

“…They are most often found at the ends of long bones and account for 5% of all primary bone tumors and 20% of all benign bone tumors [ 2 ]. The GCTB incidence is 1.3 per million persons per year based on a population study conducted in Sweden, which reported a female predominance with a female to male ratio of 1.3-1.5:1 [ 3 ]. GCTB emerge following skeletal maturity, with a peak incidence among those in their 20s and 30s [ 4 ].…”

“…GCTB emerge following skeletal maturity, with a peak incidence among those in their 20s and 30s [ 4 ]. The clinical features include swelling, pain, and limitations in joint movement [ 3 ]. Around half of GCTB arise around the knee joint, either affecting the distal femur or proximal tibia [ 1 ].…”